Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Einsele H, et al. Among authors: van de donk nwcj. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24. Adv Ther. 2024. PMID: 38402374 Free PMC article.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: van de donk nwcj, van brummelen emj, de boer cj. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Rodriguez-Otero P, et al. Among authors: van de donk nwcj. Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. Lancet Oncol. 2024. PMID: 38697166 Review.
T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.
Verkleij CPM, O'Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, Kruyswijk S, Baglio SR, Skerget S, Montes de Oca R, Zweegman S, Verona RI, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: van de donk nwcj. Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-3333. Online ahead of print. Clin Cancer Res. 2024. PMID: 38687588
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, Lau OS, Nielsen K, Davis C, Patel JH, Banerjee A, Stephenson T, Uhlar C, Kobos R, Goldberg JD, Pei L, Trancucci D, Girgis S, Wang Lin SX, Wu LS, Moreau P, Usmani SZ, Bahlis NJ, van de Donk NWCJ, Verona R. Cortes-Selva D, et al. Among authors: van de donk nwcj. Blood. 2024 Apr 24:blood.2023022823. doi: 10.1182/blood.2023022823. Online ahead of print. Blood. 2024. PMID: 38657201
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. Rodriguez-Otero P, et al. Among authors: van de donk nwcj. Blood Cancer J. 2024 Mar 6;14(1):40. doi: 10.1038/s41408-024-01018-6. Blood Cancer J. 2024. PMID: 38448422 Free PMC article. No abstract available.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. Rodriguez-Otero P, et al. Among authors: van de donk nwcj. Blood Cancer J. 2024 Feb 2;14(1):24. doi: 10.1038/s41408-023-00966-9. Blood Cancer J. 2024. PMID: 38307865 Free PMC article. Review.
Monoclonal Antibodies in the Treatment of Multiple Myeloma.
van de Donk NWCJ, Zweegman S. van de Donk NWCJ, et al. Hematol Oncol Clin North Am. 2024 Apr;38(2):337-360. doi: 10.1016/j.hoc.2023.12.002. Epub 2023 Dec 26. Hematol Oncol Clin North Am. 2024. PMID: 38151402 Review.
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk NWCJ, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K. Moreau P, et al. Among authors: van de donk nwcj. Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19. Adv Ther. 2024. PMID: 38110653 Free PMC article.
193 results